Osteopore Ltd. · ASX:OSX
Osteopore — Investor Presentation (August 2022)
22 slides from Osteopore's investor presentation, Aug 10, 2022
Slide 1: Investor Presentation August 2022
For personal use only INVESTOR PRESENTATION AUGUST 2022 ASX: OSX
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Osteopore Limited and its related entities (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not tr
Slide 3: Osteopore: global leader in regenerative medical technology and devices
BONE For personal use only Commercial products already available Osteopore is a global leader in regenerative medical technology and devices. Our novel implants empower natural tissue regeneration and dissolve over time. Over 60,000 successful cases with superior results over traditional procedures.
Slide 4: ASX Regenerative Medtech Landscape
ASX REGENERATIVE MEDTECH LANDSCAPE $1.13bn For personal use only $604.92m BREAKTHROUGH TECHNOLOGY $298.17m $258.78m $38.81m DE-RISKED $83.77m $36.80m $29.16m $58.74m BUSINESS MODEL $15.24m $9.87m $1.11m $0m $1.02m GLOBAL EXPANSION UNDERWAY FY Dec 21 FY June 21 FY June 21 FY June 21 FY March 22 FY Ju
Slide 5: Mission, Vision and Impact
For personal use only MISSION Harness our superior technology to become the standard of care globally for natural tissue regeneration. VISION OUR PURPOSE Become the most valuable regenerative medical device company in the world. IMPACT Improve clinical outcomes and patient quality-of-life, and reduc
Slide 6: Novel Process to Regenerate Bone
For personal use only NOVEL PROCESS TO REGENERATE BONE Our 3D printed bioresorbable implants enable the natural stages of bone healing. Highly customisable to biomimic bone and other tissues. Naturally dissolves and leaves only healthy bone tissue. Easily integrated into current clinical procedures.
Slide 7: Our Process to Regenerate Bone
OUR PROCESS TO REGENERATE BONE For personal use only Patient with Patient undergoes CT scan converted cranial defect CT scan into a 3D model Novel 3D printing Implant fits perfectly Bone grows on implant. of implant into defect Implant then dissolves. OSTEOPORE.COM 7
Slide 8: Overcoming Problems of Traditional Procedures
OVERCOMING PROBLEMS OF TRADITIONAL PROCEDURES For personal use only PERMANENT IMPLANTS BONE GRAFT US$100BN MARKET 1 US$3.9BN MARKET 2 25 – 33% 6-19% 0.01% Complication Complication Complication Rates 3,4,5 Rates 6,7,8 Rate Superior, commercially ready Permanent implants are The ‘gold standard’ bone
Slide 9: Products for Clinical Applications in Craniofacial Reconstruction
PRODUCTS FOR CLINICAL APPLICATIONS IN CRANIOFACIAL RECONSTRUCTION For personal use only PSI Bioresorbable implant that is used Bioresorbable implant that is Bioresorbable implant that is used in Patient Specific Implants (PSI) based on in neurosurgery for covering burr used in craniofacial surgery t
Slide 10: Commercial Priorities to Build Company Value
COMMERCIAL PRIORITIES TO BUILD COMPANY VALUE For personal use only EXPANDING SALES GAINING FURTHER Further sales distribution agreements REGULATORY ACCESS anticipated to be secured throughout Regulatory clearances already secured in 2022, and investigating potential many major markets, with multiple
Slide 11: Encouraging Commercial Outlook
For personal use only ENCOURAGING COMMERCIAL OUTLOOK QUARTERLY SALES REVENUE IN SGD (THOUSAND) $500 $450 $422 $431 Highly encouraging commercial outlook as the effects $400 $391 $372 of COVID-19 diminish across Osteopore’s key markets. $348 $350 $327 $308 $307 Increasing engagement with hospitals, s
Slide 12: Growing Global Sales Network
GROWING GLOBAL For personal use only SALES NETWORK Osteopore has built a robust distribution, marketing and sales network encompassing more than 20 countries. Significant access to health professionals, hospitals and health services across every continent. Ability to rapidly launch new products acro
Slide 13: Exploring Partnerships & Acquisitions
EXPLORING For personal use only PARTNERSHIPS & ACQUISITIONS Osteopore is currently investigating the viability of potential acquisition and partnership opportunities, that could have the following benefits; Partnering with industry peers to cross sell products that generate efficiencies and synergie
Slide 14: Expanding Regulatory Access
For personal use only Israel China EXPANDING Japan REGULATORY Egypt ACCESS Brazil Jordan Current regulatory clearances Near term additional target jurisdictions America Europe Australia Singapore Korea Philippines OSTEOPORE.COM 14
Slide 15: 3D Printed Implants Proprietary Technology
3D PRINTED IMPLANTS PROPRIETARY TECHNOLOGY WE ARE IMPROVING For personal use only OUR TECHNOLOGY DESIGN CENTRE OF EXCELLENCE Co-localisation of high value design workflow within vicinity of key university and hospital ecosystems for increased touch-points with key clinicians. Rapid design, manufactu
Slide 16: Developing New Applications
DEVELOPING NEW APPLICATIONS For personal use only ORAL DENTAL Product R&D Preclinical Research Clinical Trials Regulatory Approvals Initial Sales MAXILLOFACIAL Product R&D Preclinical Research Clinical Trials Regulatory Approvals Initial Sales Socket preservation Cleft palate reconstruction Guided B
Slide 17: Innovative Research Programs
INNOVATIVE RESEARCH PROGRAMS For personal use only ACCELERATING BONE REGENERATION OF OTHER PRODUCTS FOR REGENERATION TISSUE TYPES VETERINARY MARKETS Osteopore is developing materials Developing new implant scaffolds Developing surgical applications for to accelerate bone regeneration; to regenerate
Slide 18: Future Milestones
FUTURE MILESTONES For personal use only Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 SALES NETWORK EXPANSION CY22 CY22 CY22 CY22 CY23 CY23 CY23 CY23 Australia Relaunch Switzerland launch Spain Launch USA Houston Launch Germany Relaunch South Africa launch Nordic Launch UK Relaunch USA VA Hospital Launch (Houston) USA-wi
Slide 19: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only TRANSFORMATIVE BONE LOW RISK PROFILE REGENERATION PRODUCTS Clinical Reg Superior products with extremely R&D Approvals Sales Trials low probability of issues after surgery compared to bone grafts and permanent implants. SYSTEMATIC REVENUE ESTABLISHED & GRO
Slide 20: Highly Credentialed Team
HIGHLY CREDENTIALED TEAM For personal use only MARK LEONG PROF TEOH SWEE HIN DANIEL OW GOH KHOON SENG LIM JING, PHD EXECUTIVE CHAIRMAN NON-EXECUTIVE DIRECTOR NON-EXECUTIVE DIRECTOR CEO COO & CTO 23 years corporate and Adjunct Professor NTU, 35 years 33 years MedTech 15 years focused research in Over
Slide 21: For personal use only
For personal use only Mark Leong Executive Chairman E: mark_leong@osteopore.com Goh Khoon Seng Chief Executive Officer E: goh_khoon_seng@osteopore.com Lim Jing Chief Operating Officer | Chief Technology Officer E: lim_jing@osteopore.com
Slide 22: Sources
SOURCES For personal use only 1 Allied Market Research - Permanent Implant Sales 2 BCC Research - Bone Graft Substitutes Market by 2025 3 Giese, H., Meyer, J., Unterberg, A., & Beynon, C. (2020). Long-term complications and implant survival rates after cranioplastic surgery: a single-center study of